Pilot Study of Pancreatic Cancer Screening

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Sep 17, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at how often routine MRI scans show unusual findings in people who have specific genetic mutations linked to breast and pancreatic cancer. The study focuses on individuals with mutations in the BRCA1, BRCA2, ATM, or PALB2 genes. By understanding how often these abnormal results occur, researchers hope to improve cancer screening and treatment options for people at risk of pancreatic cancer.

To participate, individuals must be at least 18 years old and have a documented genetic mutation related to this study. There are two groups: one includes those with a strong family history of pancreatic cancer, while the other includes those without such a history but who are at least 50 years old. Participants will need to provide consent and be able to follow study procedures. It's important to note that people with active pancreatic cancer or pregnant women cannot join this study. If eligible, participants can expect to undergo routine MRI scans as part of the screening process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ability to provide consent and willing, and able to comply with study procedures Ability to read and speak English
• GROUP I:
• • Documentation of pathogenic or likely pathogenic germline BRCA 1 and 2, ATM or PALB2 germline genetic mutation
• • No strong family history of pancreatic cancer (defined as having \>= 1 first-degree or second-degree relative with a history of pancreatic cancer)
• • Age \>= 50 years old at time of consent.
• GROUP II:
• • Documentation of pathogenic or likely pathogenic germline BRCA 1 and 2, ATM, or PALB2 germline genetic mutation
• • Has strong family history of pancreatic cancer (defined as having \>= 1 first-degree or second-degree relative with a history of pancreatic cancer)
• • Age \>= 18 years old at time of consent (screening generally begins 10 years prior to the earliest pancreatic cancer in the family)
• Exclusion Criteria:
• • Prior or active pancreatic cancer.
• • Pregnant women are excluded from this study because effects of an MRI on developing fetus is unknown.